FDA expands limited toxicology test system premarket notification exemptions
Oct 11, 2026 edition · GC-2026-0258 · Published 2026-10-11 · Version 3 · Effective
FDA's October 6 order expands certain clinical toxicology 510(k) exemptions to qualifying federal drug-testing uses. The devices remain Class II, with employment/insurance labeling and general exemption limitations; the order does not exempt ordinary clinical diagnostic uses wholesale.
What happened
FDA's final order effective October 6 removes the federal-drug-testing exception from the existing partial premarket-notification exemptions for 14 specified Class II toxicology test-system categories. The change follows the May proposal and public comments and extends the exemption to qualifying federal testing programs. It concerns whether a 510(k) submission is needed for the defined device and intended use, rather than reclassifying these systems out of Class II or declaring every drug-testing product exempt.
The amended classifications retain employment- or insurance-testing-only use and the corresponding labeling statement, together with the general limitations in 21 CFR 862.9. A device exceeding those limits still needs premarket notification. FDA explains that other applicable requirements, including federal testing-program standards where applicable, remain distinct from the 510(k) exemption. Thus the exemption should be assessed against the particular classification, intended use, technology, and labeling, without assuming permission for broader clinical testing or treating exemption as product-specific FDA clearance.
Scope and timing
- Authority status
- Effective
- Applicability
- Potentially applicable
- Audience
- Health-tech
- Jurisdiction
- Federal
Why it matters
The exemption remains limited to specified product codes and employment or insurance testing, with labeling and scientific-technology limits. It does not exempt all clinical toxicology diagnostics or remove other device controls.
Recommended action
Regulatory affairs should map each marketed product to the order's table and 21 CFR 862.9 before relying on an exemption.
Sources
- FDA class II clinical toxicology exemption orderOfficial · FDA · 2026-10-06 · Source review 2026-10-11
Complete edition and supplemental material
This finding in the complete approved report →Regulatory horizons, CIA trends and implementation trackers remain in the full report.
Read the entire Compliance Sweep report →